Zenalux Biomedical, Inc.

Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, has been awarded a grant from the National Institute of Health (NIH) to further develop the Zenascope® to screen for cancer by employing imaging and reducing operator error.

Study was the first of its kind conducted using quantitative optical spectroscopy measurement for partial ischemia during partial nephrectomy

Enhanced functionality includes imaging capability, autofluorescence

Zenalux and Tulane collaborate to monitor tumor response to investigational cancer therapy

Pressure reading function allows users to dial in target pressure via user interface…

Zenalux and Roswell collaborating through Research Partnership program…

Zenascope C49 to be used in a breast tumor margin analysis study…

Zenascope™ effectively and non-destructively monitors key tissue biomarkers in...

DURHAM, NC – MARCH 21, 2013 – Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, is now offering the Zenascope™ PC1, a biological tissue spectrometer that reliably, quickly and non-destructively measures biological tissue...